aclidinium bromide (Tudorza Pressair, Bretaris, Eklira)

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

Dosage

  • a dry powder inhaler used twice daily

Adverse effects

Mechanism of action

More general terms

Component of

References

  1. FDA News Release: July 23, 2012 FDA approves Tudorza Pressair to treat chronic obstructive pulmonary disease http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm313052.htm
  2. 2.0 2.1 Prescriber's Letter 19(12): 2012 Tudorza Pressair (Aclidinium) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=281209&pb=PRL (subscription needed) http://www.prescribersletter.com
  3. 3.0 3.1 Wise RA et al. Effect of aclidinium bromide on major cardiovascular events and exacerbations in high-risk patients with chronic obstructive pulmonary disease: The ASCENT-COPD randomized clinical trial. JAMA 2019 May 7; 321:1693 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31063575 https://jamanetwork.com/journals/jama/fullarticle/2732574

Database